Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study - PubMed
4 days ago
- #immunotherapy
- #anti-PD-1 resistance
- #melanoma
- Study focuses on resistance to anti-PD-1 immunotherapy in stage III and IV melanoma.
- Real-world data was collected from 22 sites across six countries, involving 738 patients.
- Primary resistance and late relapse were observed in 22.1% and 25.0% of adjuvant setting patients, respectively.
- In the advanced setting, primary resistance, secondary resistance, and late progression were noted in 44.6%, 10.0%, and 12.9% of patients, respectively.
- Resistance types varied significantly by factors like country, race, BRAF mutation type, and PD-L1 expression.
- Mean time to resistance was 47.7 months in the adjuvant setting and 24.2 months in the advanced setting.
- Patients with primary resistance had the poorest overall survival.
- Clinician-assigned progression had an 87.2% positive predictive value compared to independent central reviewers.
- The study highlights a significant unmet medical need with 47.1% and 67.5% resistance rates in adjuvant and advanced settings, respectively.
- Funding and conflicts of interest include institutional support from Merck Sharp & Dohme LLC and various financial disclosures from authors.